How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Is the company’s proposed population the population that would benefit most from liraglutide?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Liraglutide for managing overweight and obesity

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about liraglutide

Marketing authorisation indication

2.1 Liraglutide (Saxenda, Novo Nordisk) is indicated 'as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial BMI of ≥30 kg/m² (obese), or ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea'.

Dosage in the marketing authorisation

2.2 The starting dosage is 0.6 mg once daily by subcutaneous injection. The dosage should be increased to 3.0 mg once daily in increments of 0.6 mg with at least 1-week intervals to improve gastro-intestinal tolerability. If escalation to the next dose step is not tolerated for 2 consecutive weeks, consider stopping treatment. Daily doses higher than 3.0 mg are not recommended. Treatment should be stopped after 12 weeks on the 3.0 mg per day dosage if the patient has not lost at least 5% of their initial body weight. For full details of dose schedules, see the summary of product characteristics.

Price

2.3 The list price of liraglutide (Saxenda) is £196.20 for 5 x 6 mg/ml 3‑ml (18 mg) pre-filled pens. The company has a commercial arrangement, which would have applied if the technology had been recommended.